Merz Therapeutics GmbH

5 trials 2 recruiting Commercial sponsor Merged from 2 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

13 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 4 Phase II: 1

Oversight events:

2 corrective measures across 2 trials

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 3

All trials

5 total

A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting

2024-515682-34-00 Phase III 9 countries
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting

2024-515715-22-00 Phase III 9 countries
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok… Ended

2023-505810-12-00 Phase III 9 countries CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
A clinical trial to investigate efficacy and safety of NT 201 injections compared with placebo injections in participants aged 18 years and … Ended

2022-501461-52-00 Phase II 6 countries CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with… Ended

2023-503420-19-00 Phase III 2 countries CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS

Showing 1–5 of 5 trials

← All sponsors A–Z